Elavi Labs Shares Are Trading Higher After the Company Announced the Launch of Elevai Biosciences and Elevai Skincare. Also, the Company Announced Results From Its Licensor's 2022 Preclinical Studies Evaluating the Treatment Effect of EL-22.
Elavi Labs Shares Are Trading Higher After the Company Announced the Launch of Elevai Biosciences and Elevai Skincare. Also, the Company Announced Results From Its Licensor's 2022 Preclinical Studies Evaluating the Treatment Effect of EL-22.
在該公司宣佈推出Elevai Biosciences和Elevai Skincare之後，該公司股價走高。此外，該公司還公佈了其許可方2022年評估 EL-22 治療效果的臨床前研究結果。
Elavi Labs Shares Are Trading Higher After the Company Announced the Launch of Elevai Biosciences and Elevai Skincare. Also, the Company Announced Results From Its Licensor's 2022 Preclinical Studies Evaluating the Treatment Effect of EL-22.
在該公司宣佈推出Elevai Biosciences和Elevai Skincare之後，該公司股價走高。此外，該公司還公佈了其許可方2022年評估 EL-22 治療效果的臨床前研究結果。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。